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Table 2. Overview of results of published economic evaluations of pharmacological interventions for bipolar disorder 
Results listed by form of economic evaluation (CUA, CEA or CCA); within CEAs, results listed by outcome measure used 
 
Study ID 
Country, currency and 
cost year 
Base-case results in original currency (2016 US$) Results of sensitivity analysis 
Cost-utility analyses 
Management of manic / mixed episodes and/or rapid cycling in adults with BD 
Caresano et al., 2014 [20] 
Italy, Euro(€), 2014 
Ase dominates Olz PSA: Probability of Ase being cost-effective 0.63 and 0.72 at WTP of 
zero/QALY and €30,000/QALY, respectively 
Results robust to different assumptions in resource use; conclusions 
robust to changes in transition probabilities between non-response, stable 
health state and sub-acute health state. 
Sawyer et al., 2014 [24] 
UK, GBP£, 2013 
Ase vs Olz: £1302 ($1946) per QALY PSA mean results: Ase dominant 
Probability of Ase being cost-effective 0.51, 0.61 and 0.65 at WTP of 
zero/QALY, £20,000/QALY and £30,000/QALY, respectively. 
Results sensitive to changes in short and longer-term efficacy; 
conclusions robust to changes in time horizon, unit costs and utility 
values 
Management of manic, hypomanic and/or mixed episodes in children & young people with BD 
Uttley et al., 2013 [25] 
UK, GBP£, 2011 
Sequencing strategy 2 (Ris, Ari, Que, Li) dominates all other 
sequencing strategies (i.e. strategy 1: Ris, Que, Olz, Li; strategy 3: 
Ari, Ris, Que, Li; strategy 4: Ris, Que, Ari, Li) 
PSA conducted 
Results very sensitive to consideration of personalised medicine, 
reflected in small changes (1-2%) in costs and QALYs (strategy 2 
becomes dominated by all other strategies) 
Management of depressive episodes in adults with bipolar disorder 
Ekman et al., 2012 [18] 
UK, GBP£, 2011 
Que+MS dominates all other strategies (i.e. Que, Olz, Olz+Li with 
Olz replaced by Ven or Par in acute depression, Ari replaced by 
Olz+Ven  in acute depression, Ris in mania, Ven+Li in depression, 
Olz in maintenance [Mixed]) 
Que dominates all strategies except Olz and Mixed 
Que vs Olz: £8591 ($13,033) per QALY 
Que vs Mixed: £18,570 ($30,164) per QALY 
  
PSA: Compared with Olz, probability of Que being cost-effective at WTP 
zero/QALY and £30,000/QALY: 0.21; 0.90 
Results (Que vs Olz) robust to changes in inpatient or outpatient costs, 
starting age of the cohort, disutilities for discontinuation and side effects; 
sensitive to inclusion of indirect costs, use of a 6% discount rate, changes 
in time horizon, treatment discontinuation and dosages 
Maintenance treatment of adults with BD 
Calvert et al., 2006 [27] 
US, US$, 2004 
All drugs dominate no treatment 
Lam dominates Olz 
Lam vs Li: $26,000 ($33,151) per QALY 
:  
Results robust to changes in length of acute episodes and length of 
hospitalisation. Results sensitive to changes in transition probabilities and 
costs of maintenance treatments. 
Study ID 
Country, currency and 
cost year 
Base-case results in original currency (2016 US$) Results of sensitivity analysis 
Soares-Weiser et al., 2007 
UK, GBP£, 2005 [31] 
 
Most recent episode depressive: 
Car, Imi, Lam and Olz dominated  
Li vs Val £10,409 ($20,178) per QALY 
Li+Imi vs Li £21,370 ($41,426) per QALY 
Most recent episode manic: 
Car, Imi, Lam, Li+Imi and Val dominated 
Li vs Olz £11,359 ($22,020) per QALY 
  
Most recent episode depressive: 
PSA: Probability of cost effectiveness at WTP £20,000/QALY: Car 0.00; 
Imi 0.00; Lam 0.05; Li 0.36; Li+Imi 0.47; Olz 0.00; Val 0.12          
Most recent episode manic: 
PSA: Probability of cost effectiveness at WTP £20,000/QALY: Car 0.00; 
Imi 0.00; Lam 0.00; Li 0.77; Li+Imi 0.09; Olz 0.11; Val 0.02         
Results robust to alternative approaches for handling missing data; 
variation in RCTs included in the analysis; and alternative discount rates. 
Results sensitive to the assumption that Li reduces mortality. 
Fajutrao et al., 2009 [28] 
UK, GBP£, 2007 
Que+MS dominates MS alone PSA: probability of Que+MS being cost-effective at zero WTP /QALY: 
0.82 
Results most sensitive to risk and length of hospitalisation, cost of 
hospital stay, and Que acquisition cost 
Woodward et al., 2009 [32] 
US, US$, 2007 
 
Que+MS dominates MS alone 
 
PSA: Probability of Que+MS being cost-effective at WTP of 
$50,000/QALY: 1.00 
Results most sensitive to Que acquisition cost, risk and length of 
hospitalisation for acute episodes (especially manic), cost of inpatient 
treatment for a manic episode 
Ekman et al., 2012 [18] 
UK, GBP£, 2011 
 
 
 
Que+MS dominates all other strategies (i.e. Que, Olz, Olz+Li with 
Olz replaced by Ven or Par in acute depression, Ari replaced by 
Olz+Ven  in acute depression, Ris in mania, Ven+Li in depression, 
Olz in maintenance [Mixed]) 
Que dominates all strategies except Olz and Mixed 
Que vs Olz: £27,437 ($44,568) per QALY 
Que vs Mixed: £41,691 ($67,722) per QALY 
PSA: Compared with Olz, probability of Que being cost-effective at WTP 
zero/QALY and £30,000/QALY: 0.29; 0.92, respectively 
Results of deterministic sensitivity analysis not presented for this 
population 
Woodward et al., 2010 [33] 
US, US$, 2009 
 
3rd party payer perspective: 
Que XR+MS dominates Lam, Olz, Ari and no treatment. 
Que XR+MS vs MS: $22,959 ($25,775) per QALY 
Que XR+MS vs Li: $100,235 ($112,530) per QALY 
Societal perspective: 
Que XR + MS dominates MS, Lam, Olz, Ari and no treatment 
Que XR+MS vs Li: $81,712 ($91,735) per QALY 
3rd party payer perspective: 
PSA: Probability of cost effectiveness at WTP $100,000/QALY: 
Que XR+MS: 50%; Li: 50% 
Results most sensitive to efficacy, utility for the euthymia state, Que XR 
acquisition cost, risk and length of hospitalisation for manic episodes, and 
cost of inpatient treatment for a manic episode 
Management of patients in any phase of BD 
Chisholm et al., 2005 [34] 
World regions, I$, likely 
2003 
All hospital-based options and all options with Val dominated 
ICER vs no treatment ranged from I$2165 ($2844) per DALY 
averted (Li+PC, community-based service model in African sub-
region that includes Nigeria, Senegal, etc.) to I$37,244 ($48,929) 
per DALY) averted (Val, hospital-based model in Western Pacific 
sub-region that includes Australia, Japan, etc.) 
Results robust to changes in suicide risk, use of alternative disability 
weights, small changes to relative effects of Li vs Val; results modestly 
sensitive to consideration of age-weights, changes in adherence, 
discount rate, resource use and costs. 
Study ID 
Country, currency and 
cost year 
Base-case results in original currency (2016 US$) Results of sensitivity analysis 
Chisholm et al., 2012 [35] 
World regions, 
International I$, 2005 
All hospital-based options and all options with Val dominated 
Li in community setting vs no treatment: I$1800 ($2228) per DALY 
averted in sub-Saharan Africa; I$2001 ($2477) per DALY averted 
in South-East Asia 
Li+PC vs Li, both in community setting: I$9,916 ($12,273) per 
DALY averted in sub-Saharan Africa; I$13,444 ($16,640) per 
DALY averted in South-East Asia 
Results robust to PSA that took account of a 15-25% variation in data 
inputs 
Cost Effectiveness analyses 
 
Outcome: number of responders or remitters 
Management of manic / mixed episodes and/or rapid cycling in adults with BD 
Bridle et al., 2004 [19] 
UK GBP£, 2002 
Hal dominates Li, Val and Que 
Olz vs Hal: £7179 ($15,313) per additional responder 
  
PSA: Probability of being best at WTP £20,000/responder: Olz 0.44; Hal 
0.37; Li 0.16; Que 0.02; Val 0.01 
Results robust to the following scenarios: 
 hospitalisation of non-responders beyond 3 weeks 
 2nd and 3rd line treatment for non-responders 
 reductions in laboratory testing costs 
 modified ITT approach 
inclusion of treatment costs for EPS caused by Hal 
Klok et al., 2007 [21] 
The Netherlands, Euro(€), 
2003 
Olz+Li, Li, Que, Val and Plc dominated 
Que+Li vs Ris+Li: €12,667 ($19,052) per additional responder 
Results robust to changes in inpatient care costs and discharge criteria; 
results sensitive to baseline and changes in YMRS scores and 
compliance 
Management of depressive episodes in adults with bipolar disorder 
Rajagopalan et al., 2015 
[26] 
US, US$, likely 2013 
Lur vs Que XR: $3474 ($3592) per additional remission PSA: Probability of Lur being cost-effective at WTP $10,000/remission: 
0.86 
Results most sensitive to remission rates and drug acquisition costs 
 
Outcome: number of acute episodes avoided 
Maintenance treatment of adults with BD 
Calvert et al., 2006 [27] 
US, US$, 2004 
All drugs dominate no treatment 
Lam dominates Olz 
Lam vs Li: $2400 ($3060) per acute episode avoided 
Results robust to changes in length of acute episodes and length of 
hospitalisation. Results sensitive to changes in transition probabilities and 
costs of maintenance treatments. 
McKendrick et al., 2007 
[29] 
UK, GBP£, 2003 
Olz dominates Li Results most sensitive to risk and length of hospitalisation for mania, cost 
of hospitalisation and time horizon 
Sensitivity analysis: results ranging from Olz being dominant to Olz vs Li 
£367 per acute episode avoided ($552 in 2016 US$ prices) 
Study ID 
Country, currency and 
cost year 
Base-case results in original currency (2016 US$) Results of sensitivity analysis 
Fajutrao et al., 2009 [28] 
UK, GBP£, 2007 
Que+MS dominates MS alone PSA: probability of Que+MS being cost-effective at zero WTP /acute 
episode avoided: 0.85 
Results most sensitive to risk and length of hospitalisation, cost of 
hospital stay, and Que acquisition cost 
Woodward et al., 2009 [32] 
US, US$, 2007 
Que+MS dominates MS alone Results most sensitive to Que acquisition cost, risk and length of 
hospitalisation for acute episodes (especially manic), cost of inpatient 
treatment for a manic episode 
Woodward et al., 2010 [33] 
US, US$, 2009 
 
 
 
3rd party payer perspective: 
Que XR+MS dominates Lam, Olz, Ari and no treatment. 
Que XR+MS vs MS: $1045 ($1174) per acute episode avoided 
Que XR+MS vs Li: $5515 ($6191) per acute episode avoided 
Societal perspective: 
Que XR + MS dominates MS, Lam, Olz, Ari and no treatment 
Que XR+MS vs Li: $4496 ($5047) per acute episode avoided 
Results most sensitive to efficacy, utility for the euthymia state, Que XR 
acquisition cost, risk and length of hospitalisation for manic episodes, and 
cost of inpatient treatment for a manic episode 
 
Outcome: number of euthymic days gained 
Maintenance treatment of adults with BD 
Calvert et al., 2006 [27] 
US, US$, 2004 
All drugs dominate no treatment 
Lam dominates Olz 
Lam vs Li: $30 ($38) per extra euthymic day 
Results robust to changes in length of acute episodes and length of 
hospitalisation. Results sensitive to changes in transition probabilities and 
costs of maintenance treatments. 
 
Outcome: number of inpatient days avoided or % of people hospitalised due to an acute episode 
Management of manic / mixed episodes and/or rapid cycling in adults with BD 
Klok et al., 2007 [21] 
The Netherlands, Euro(€), 
2003 
Ris+Li dominates all other options (Que, Li, Val, Que+Li, Olz+Li, 
Plc) in terms of number of inpatient days avoided 
 
Results robust to changes in inpatient care costs and discharge criteria; 
results sensitive to baseline and changes in YMRS scores and 
compliance 
Maintenance treatment of adults with bipolar disorder 
Fajutrao et al., 2009 [28] 
UK, GBP£, 2007 
Que+MS dominates MS alone  in terms of % of people 
hospitalised due to an acute episode 
PSA: probability of Que+MS being cost-effective at zero WTP 
/hospitalisation avoided: 0.85 
Results most sensitive to risk and length of hospitalisation, cost of 
hospital stay, and Que acquisition cost 
Woodward et al., 2009 [32] 
US, US$, 2007 
Que+MS dominates MS alone in terms of % of people hospitalised 
due to an acute episode 
Results most sensitive to Que acquisition cost, risk and length of 
hospitalisation for acute episodes (especially manic), cost of inpatient 
treatment for a manic episode 
Study ID 
Country, currency and 
cost year 
Base-case results in original currency (2016 US$) Results of sensitivity analysis 
Woodward et al., 2010 [33] 
US, US$, 2009 
 
 
 
3rd party payer perspective: 
Que XR+MS dominates Lam, Olz, Ari and no treatment. 
Que XR+MS vs MS: $3464 ($3889) per hospitalisation avoided 
Que XR+MS vs Li: $21,112 ($23,702) per hospitalisation avoided 
Societal perspective: 
Que XR + MS dominates MS, Lam, Olz, Ari and no treatment 
Que XR+MS vs Li: $17,211 ($19,322) per hospitalisation avoided 
Results most sensitive to efficacy, utility for the euthymia state, Que XR 
acquisition cost, risk and length of hospitalisation for manic episodes, and 
cost of inpatient treatment for a manic episode 
 
Outcome: number of major side effects avoided 
Management of manic / mixed episodes and/or rapid cycling in adults with BD 
Klok et al., 2007 [21] 
The Netherlands, Euro(€), 
2003 
 
Que, Li, Que+Li, Olz+Li dominated 
Val vs Ris+Li: €399 ($599) per major side effect avoided 
Plc vs Val: €317,667 ($477,784) per major side effect avoided 
Results robust to changes in inpatient care costs and discharge criteria; 
results sensitive to baseline and changes in YMRS scores and 
compliance 
Cost consequence analyses 
Management of manic / mixed episodes and/or rapid cycling in adults with BD 
Namjoshi et al., 2002 
[22] 
US, US$, 1995 
Total monthly medical costs per person for Olz: 
Open label phase: mean $649 ($1026), SD $399 ($631); 
Pre-randomisation: mean $1533 ($2423), SD $2262 ($3575); 
p<0.01  
 
Changes in YMRS scores at 3 weeks: 
Olz: -10.3 (baseline 28.6), Plc: -4.9 (baseline 27.6); p=0.02 
 
Changes in SF-36 dimension scores at 3 weeks: 
Significantly better change score for Olz in physical functioning 
(p=0.02); no statistically significant differences in other dimensions 
 
Open label extension: 
Change in YMRS score for Olz: 7.5 (baseline 19.3); p<0.01 
Significant improvements in SF-36 dimensions of bodily pain, 
vitality, general health, role-emotional and social functioning 
NA 
Study ID 
Country, currency and 
cost year 
Base-case results in original currency (2016 US$) Results of sensitivity analysis 
Revicki et al., 2003 [23] 
US, US$, 1992 
Total medical costs per person: 
Val mean $13,703 ($23,524), SD $8,708 ($14,949); 
Olz mean $15,180 ($ 26,060), SD $16,780 ($28,806); p=0.88 
 
Changes in MRS scores: 
Val: -14.9 (baseline 30.8); Olz -16.6 (baseline 32.3); p=0.368 
 
Changes in Q-LES-Q scores (subjective feelings): Val -4.4, Olz -
4.7; p=0.95 
 
No statistically significant differences in any other outcomes 
NA 
Maintenance treatment of adults with bipolar disorder  
Revicki et al, 2005 [30] 
US, US$, 1997 
Total medical costs per person: 
Val mean $28,911 ($43,385), SE $3599 ($5401); 
Li mean $30,666 ($46,019), SE $7364 ($11,051); p = 0.693 
 
Mean number of months without DSM-IV mania or depression 
(SD): 
Val 5.3 (4.6); Li 5.4 (4.4), p = 0.814 
Non-significant differences in any other outcomes between groups 
NA 
 
Cost effectiveness figures converted and uplifted to 2016 US dollars using purchasing power parity (PPP) exchange rates (http://www.oecd.org/std/ppp) and 
the US Consumer Price Index (http://www.usinflationcalculator.com/) 
 
Table abbreviations: 
BD: bipolar disorder; DALY: Disability Adjusted Life Year; ICER: Incremental Cost Effectiveness Ratio; NA: non-applicable; PSA: probabilistic sensitivity 
analysis; SD: Standard Deviation; SE: Standard Error 
 
Abbreviations of drug names used in the table: 
Ari: Aripiprazole; Ase: Asenapine; Car: Carbamazepine; Hal: Haloperidol; Imi: Imipramine; Lam: Lamotrigine; Li: Lithium; Lur: Lurasidone; MS: mood 
stabiliser; Olz: Olanzapine; Par: Paroxetine; PC: Psychosocial Care; Plc: Placebo; Que: Quetiapine; Que XR: Quetiapine extended release; Ris: Risperidone; 
Val: Valproic acid or sodium valproate; Ven: Venlafaxine 
